Answers are grounded in this paper and cite their sources.
Objective: The effect of COVID-19 mRNA vaccines on prostate specific antigen (PSA) levels in prostate cancer patients remains unclear. In this study, we aimed to evaluate the effects of COVID-19 mRNA vaccination on PSA levels in patients with prostate cancer. Method: Retrospective data were collected from patients diagnosed with prostate cancer (ICD-10 code C61). Inclusion criteria encompassed patients with pre-vaccination PSA levels of ≤2 ng/mL, no metastases, no active urinary tract infection and no history of urinary catheterization. Results: Of the 333 patients initially screened, 176 were excluded due to missing data. Sixty-eight patients with PSA level > 2 ng/mL and 10 patients who developed urinary tract infection during follow-up were also excluded. The study included 89 patients (mean age: 70.77±5.88 years). Fifteen of these patients were between the ages of 55-65 years and the remaining 64 patients were between the ages of 65-83 years. There was no significant difference in PSA measurements between the first, second, and third doses of COVID-19 mRNA vaccine. Conclusion: Invaluable information about the effect of COVID-19 mRNA vaccination on PSA levels in prostate cancer patients was provided. The findings suggest that COVID-19 mRNA vaccination has no significant effect on PSA levels in prostate cancer patients admitted to our urology and oncology clinics. However, further studies with larger sample size and longer follow-up period are needed to confirm these findings and better understand the relationship between COVID-19 vaccination and PSA levels in prostate cancer patients.
No takes yet. Share an insight, caveat, or question.
Börekoğlu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: